Loading clinical trials...

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (25 and 50 mg/Day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder

NCT00798707•Pfizer

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)
•Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \>= 20
•Clinical Global Impressions Scale-Severity (CGI-S) score of \>= 4

Exclusion Criteria

•Clinical instability - 25% or greater increase/decrease in HAM-D 17 total score from screening to baseline
•Significant risk of suicide as assessed by clinician judgement, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply

Locations (78)

Pfizer Investigational Site

Arcadia, California, United States

Pfizer Investigational Site

Beverly Hills, California, United States

Pfizer Investigational Site

Cerritos, California, United States

Pfizer Investigational Site

Garden Grove, California, United States

Pfizer Investigational Site

Los Alamitos, California, United States

Pfizer Investigational Site

St. Petersburg, Florida, United States

Pfizer Investigational Site

Atlanta, Georgia, United States

Pfizer Investigational Site

Smyrna, Georgia, United States

Pfizer Investigational Site

Libertyville, Illinois, United States

Pfizer Investigational Site

Dayton, Ohio, United States

Key Dates

Start Date

December 1, 2008

Primary Completion Date

April 1, 2010

Completion Date

April 1, 2010

Last Updated

June 10, 2011

Enrollment

709

ACTUAL participants

Conditions

Major Depressive Disorder

Interventions

Desvenlafaxine Succinate Sustained-Release (DVS SR)

DRUG

Desvenlafaxine Succinate Sustained-Release (DVS SR)

DRUG

placebo

DRUG

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 10, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use